Shanghai Rendu Biotechnology Co (SHSE:688193) EV-to-EBIT : -44.50 (As of Jun. 02, 2025)

Shanghai Rendu Biotechnology Co EV-to-EBIT Chart

Shanghai Rendu Biotechnology Co Quarterly Data
	Dec18	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBIT	Get a 7-Day Free Trial															40.81	16.91	25.66	-44.32	-38.56

Competitive Comparison of Shanghai Rendu Biotechnology Co's EV-to-EBIT

For the Diagnostics & Research subindustry, Shanghai Rendu Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Rendu Biotechnology Co's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Shanghai Rendu Biotechnology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shanghai Rendu Biotechnology Co's EV-to-EBIT falls into.

Shanghai Rendu Biotechnology Co EV-to-EBIT Calculation

Shanghai Rendu Biotechnology Co's EV-to-EBIT for today is calculated as:

Shanghai Rendu Biotechnology Co's current Enterprise Value is ¥791.6 Mil.
Shanghai Rendu Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-17.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Rendu Biotechnology Co  (SHSE:688193) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Shanghai Rendu Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Shanghai Rendu Biotechnology Co's Enterprise Value for the quarter that ended in Mar. 2025 was ¥686.0 Mil.
Shanghai Rendu Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-17.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Rendu Biotechnology Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Shanghai Rendu Biotechnology Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Rendu Biotechnology Co Business Description